Allena Pharmaceuticals (NASDAQ:ALNA) is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.

biopharmaceuticals
Public (NASDAQ:ALNA)
Visit Website
Additional Portfolio Companies
October 4, 2020